Trial reportRheumatology (Oxford, England)2011
Minimally important differences of the gout impact scale in a randomized controlled trial.
Trial report in Rheumatology (Oxford, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00610363 (A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study, Tolerability, and Efficacy of Rilonacept for the Prevention of Gout Flares During Initiation of Allopurinol Therapy), which is not on this map. Cited by 18 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study, Tolerability, and Efficacy of Rilonacept for the Prevention of Gout Flares During Initiation of Allopurinol Therapy
Who cites it
18 citing papers in PubMed, 5 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- A Systematic Review of the Economic and Humanistic Burden of Gout.PharmacoEconomics · 2015Pooled it
- Uricosuric medications for chronic gout.The Cochrane database of systematic reviews · 2014Pooled it
- Allopurinol for chronic gout.The Cochrane database of systematic reviews · 2014Pooled it
- Health-related quality of life in gout: a systematic review.Rheumatology (Oxford, England) · 2013Pooled it
- Lifestyle interventions for chronic gout.The Cochrane database of systematic reviews · 2013Pooled it
- SToRytelling to Improve Disease outcomes in Gout (STRIDE-GO): a multicenter, randomized controlled trial in African American veterans with gout.BMC medicine · 2021Trial
- Reliability and Validity of the Korean Version of the Gout Impact Scale.Journal of Korean medical science · 2023Article
- Factors associated with change in health-related quality of life in people with gout: a 3-year prospective cohort study in primary care.Rheumatology (Oxford, England) · 2023Article
- Translation, internal consistency, reliability and validity of the Thai version of Gout Assessment Questionnaire version 2.0 (GAQ 2.0).Clinical rheumatology · 2022Article
- Gout management and outcomes during established COVID-19 pandemic in 2020-2021: a cross-sectional Internet survey.Therapeutic advances in musculoskeletal disease · 2022Article
- Article
- Gout management and outcomes during the COVID-19 pandemic: a cross-sectional internet survey.Therapeutic advances in musculoskeletal disease · 2020Article
- Gout Activity Score has predictive validity and is sensitive to change: results from the Nottingham Gout Treatment Trial (Phase II).Rheumatology (Oxford, England) · 2019Article
- Racial differences in health-related quality of life and functional ability in patients with gout.Rheumatology (Oxford, England) · 2017Observational
- Performance of Gout Impact Scale in a longitudinal observational study of patients with gout.Rheumatology (Oxford, England) · 2016Observational
- Health-related quality of life and treatment satisfaction in patients with gout: results from a cross-sectional study in a managed care setting.Patient preference and adherence · 2015Article
- Experiences of gout-related disability from the patients' perspective: a mixed methods study.Clinical rheumatology · 2014Article
- Patient-reported outcomes in chronic gout: a report from OMERACT 10.The Journal of rheumatology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveThe Gout Impact Scale (GIS) is a gout-specific quality of life instrument that assesses impact of gout during an attack and impact of overall gout. The GIS has five scales and each is scored from 0 to 100 (worse health). Our objective was to assess minimally important differences (MIDs) for the GIS administered in a randomized controlled trial (RCT) assessing rilonacept vs placebo for prevention of gout flares during initiation of allopurinol therapy.
methodsTrial subjects (n = 83) included those with two or more gout flares (self-reported) in the past year. Of these, 73 had data for Weeks 8 vs 4 and formed the MID analysis group and were analysed irrespective of the treatment assignment. Subjects completed the GIS and seven patient-reported anchors. Subjects with a one-step change (e.g. from very poor to poor) were considered as the MID group for each anchor. The mean change in GIS scores and effect size (ES) was calculated for each anchor's MID group. The average of these created the overall summary MID statistics for each GIS. An ES of 0.2-0.5 was considered to represent MID estimates. Results. Trial subjects (n = 73) were males (96.0%), White (90.4%), with mean age of 50.5 years and serum uric acid of 9.0 mg/dl. The mean change score for the MID improvement group for scales ranged from -5.24 to -7.61 (0-100 scale). The ES for the MID improvement group for the four scales ranged from 0.22 to 0.38.
conclusionThe MID estimates for GIS scales are between 5 and 8 points (0-100 scale). This information can aid in interpreting the GIS results in future gout RCTs. Trial Registration. Clinicaltrials.gov, www.clinicaltrials.gov, NCT00610363.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.